Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved “Steve has spent the past four years working to deeply ...
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in ...
Stocktwits on MSN
Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?
With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback